101. The EHA Research Roadmap: Malignant Lymphoid Diseases. Issue 6 (19th June 2022) Authors: Dreyling, Martin; André, Marc; Gökbuget, Nicola; Tilly, Hervé; Jerkeman, Mats; Gribben, John; Ferreri, Andrés; Morel, Pierre; Stilgenbauer, Stephan; Fox, Christopher; Maria Ribera, José; Zweegman, Sonja; Aurer, Igor; Bödör, Csaba; Burkhardt, Birgit; Buske, Christian; Dollores Caballero, Maria; Ca... Journal: HemaSphere Issue: Volume 6:Issue 6(2022) Page Start: e726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
102. The emerging therapeutic role of antibody mixtures. (August 2013) Authors: Robak, Tadeusz Journal: Expert opinion on biological therapy Issue: Volume 13:Number 7(2013:Jul.) Page Start: 953 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
103. The kinetics of hematopoietic niche cytokines and their influence on mobilization efficacy and timing in patients with hematological malignancies. Issue 4 (29th October 2014) Authors: Szmigielska‐Kaplon, Anna; Krawczynska, Anna; Czemerska, Magdalena; Pluta, Agnieszka; Cebula‐Obrzut, Barbara; Robak, Marta; Grzybowska‐Izydorczyk, Olga; Szmigielska, Katarzyna; Robak, Tadeusz; Wierzbowska, Agnieszka Journal: Journal of clinical apheresis Issue: Volume 30:Issue 4(2015) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
104. The management of hematologic malignancies during the COVID-19 pandemic. (24th March 2021) Authors: Hus, Iwona; Salomon-Perzyński, Aleksander; Tomasiewicz, Krzysztof; Robak, Tadeusz Journal: Expert opinion on pharmacotherapy Issue: Volume 22:Number 5(2021) Page Start: 565 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
105. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. (July 2015) Authors: Smolewski, Piotr; Robak, Tadeusz Journal: Expert opinion on drug discovery Issue: Volume 10:Number 7(2015:Jul.) Page Start: 791 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
106. The safety of available chemo-free treatments for mantle cell lymphoma. Issue 11 (1st November 2020) Authors: Korycka-Wołowiec, Anna; Wołowiec, Dariusz; Robak, Tadeusz Journal: Expert opinion on drug safety Issue: Volume 19:Issue 11(2020) Page Start: 1377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
107. The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Issue 2 (1st February 2017) Authors: Korycka-Wołowiec, Anna; Wołowiec, Dariusz; Robak, Tadeusz Journal: Expert opinion on drug safety Issue: Volume 16:Issue 2(2017:Feb.) Page Start: 185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
108. The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. (2nd July 2020) Authors: Hus, Iwona; Salomon-Perzyński, Aleksander; Robak, Tadeusz Journal: Expert opinion on biological therapy Issue: Volume 20:Number 7(2020) Page Start: 799 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
109. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. Issue 8 (3rd August 2015) Authors: Budziszewska, Bozena Katarzyna; Pluta, Agnieszka; Sulek, Kazimierz; Wierzbowska, Agnieszka; Robak, Tadeusz; Giebel, Sebastian; Holowiecka-Goral, Aleksandra; Sawicki, Waldemar; Ejduk, Anna; Patkowska, Elzbieta; Manko, Joanna; Gajkowska-Kulik, Justyna; Piszcz, Jaroslaw; Mordak-Domagala, Monika; Mad... Journal: Leukemia & lymphoma Issue: Volume 56:Issue 8(2015:Aug.) Page Start: 2331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
110. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Issue 6 (12th May 2022) Authors: Burger, Jan A.; Robak, Tadeusz; Demirkan, Fatih; Bairey, Osnat; Moreno, Carol; Simpson, David; Munir, Talha; Stevens, Don A.; Dai, Sandra; Cheung, Leo W. K.; Kwei, Kevin; Lal, Indu; Hsu, Emily; Kipps, Thomas J.; Tedeschi, Alessandra Journal: Leukemia & lymphoma Issue: Volume 63:Issue 6(2022) Page Start: 1375 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗